| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Email: |
orderCN@merckgroup.com |
| Products Intro: |
Product Name:PF-04449613
CAS:1236858-52-8
Purity:>=98% (HPLC) Package:5mg, 25mg Remarks:PZ0349
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:PF 04449613
CAS:1236858-52-8
Purity:≥98% by HPLC Remarks:PF 04449613 is a potent PDE9 inhibitor (IC50 = 22 nM), and also shows a high affinity for cGMP (Km ~170 nM). Some studies suggest that elevating the level of cGMP with the PDE9 inhibitor PF-04449613 i
|
| Company Name: |
ChemeGen(Shanghai) Biotechnology Co.,Ltd.
|
| Tel: |
18818260767 |
| Email: |
sales@chemegen.com |
| Products Intro: |
Product Name:PF-04449613
CAS:1236858-52-8
Purity:98% Package:10 mg;50 mg;100 mg;500 mg;1 g;5 g;10 g
|
|
| | FHBANDDJQJAZOQ-CQSZACIVSA-N Basic information |
| Product Name: | FHBANDDJQJAZOQ-CQSZACIVSA-N | | Synonyms: | FHBANDDJQJAZOQ-CQSZACIVSA-N;PF-04449613;1,5-Dihydro-6-[(1R)-1-(3-phenoxy-1-azetidinyl)ethyl]-1-(tetrahydro-2H-pyran-4-yl)-4H-pyrazolo[3,4-d]pyrimidin-4-one;4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,5-dihydro-6-[(1R)-1-(3-phenoxy-1-azetidinyl)ethyl]-1-(tetrahydro-2H-pyran-4-yl)-;PF-04449613 >=98% (HPLC);PF 04449613,PF04449613;(R)-6-(1-(3-Phenoxyazetidin-1-yl)ethyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one | | CAS: | 1236858-52-8 | | MF: | C21H25N5O3 | | MW: | 395.45 | | EINECS: | | | Product Categories: | | | Mol File: | 1236858-52-8.mol |  |
| | FHBANDDJQJAZOQ-CQSZACIVSA-N Chemical Properties |
| storage temp. | -20°C | | solubility | DMSO: 10 mg/ml | | form | powder | | color | white to beige |
| | FHBANDDJQJAZOQ-CQSZACIVSA-N Usage And Synthesis |
| Uses | PF 04449613 (cas# 1236858-52-8) is a useful research chemical. Potent PDE9 inhibitor. | | Biochem/physiol Actions | PF-04449613 is a potent and selective cGMP-competitive PDE9A inhibitor (IC50 = 24 nM; IC50 >800 nM against other PDE members), displaying more than 1000-fold selectivity over the majority of 79 non-PDE targets investigated with the exception of cytochrome P450 2C19 (IC50 = 1600 nM), dopamine transporter (Ki = 110 nM), μ-opioid receptor (Ki = 3500 nM), and sodium channel binding site 2 (Ki = 470 nM). PF-4449613 is shown to effectively increase cGMP levels in brain (1-10 mg/kg s.c.; mice) and CSF (1-32 mg/kg s.c.; rats and cynomolgus macaques) in vivo with good brain penetration (brain/plasma ratio of 0.8 in mice). PF-04449613 is effective against D-amphetamine-induced auditory gating deficit (by 43% with 1 mg/kg PF-04449613 s.c.; 1 mg/kg AMP i.v.) and transverse aortic constriction-caused cardiac dysfunction (30 mg/kg/12 h p.o.) in mice in a NOS-independent manner. | | storage | Store at -20°C |
| | FHBANDDJQJAZOQ-CQSZACIVSA-N Preparation Products And Raw materials |
|